



PRESS RELEASE

KPI Therapeutics Nominated for the Buzz of Bio for its Promising Pipeline

SEATTLE, April 5, 2017 – KPI Therapeutics Inc., a clinical stage biotechnology company today has been nominated by the Biotechnology Innovation Industry (BIO) as one of the finalists in their Buzz of Bio competition in the “Pipelines of Promise” category. The competition which is held in connection with BIO’s annual international meeting has 40 nominees, and the company in each of two categories which gains the most votes from the biotech community after one week is selected as the winner and receives industry recognition as well as other benefits from BIO. KPI’s pipeline includes dalazatide which is expected to begin clinical trials in 2017 in both myositis and in lupus KPI is also developing KPI-150, a topical cream for atopic dermatitis, and KPI-190 an eye drop for uveitis and autoimmune dry eye disease. Read more about the competition and the nominated companies at:

<http://convention.bio.org/buzzofbio/voting.aspx>

About KPI Therapeutics

KPI Therapeutics is a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity, the current immediate focus of KPI is

on advancing clinical programs in both myositis and lupus. For more information about KPI please visit our website: www.kpitherapeutics.com

About dalazatide, KPI-150 and KPI-190

Dalazatide is a Kv1.3 inhibitor with a novel mechanism of action (MOA). Preclinical and clinical data have shown that dalazatide is a selective and potent blocker of the voltage-gated Kv1.3 potassium channel - a key channel in the activation of effector memory T-cells. Effector memory T-cells are implicated in the pathology of many autoimmune diseases. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. Dalazatide is being studied as a potential therapy for multiple autoimmune diseases and KPI is planning to begin studies in myositis and lupus in 2017. A Phase 1b study in psoriatic arthritis was completed as well as two other Phase 1 trials.

Topical KPI-150 and eye drop KPI-190 are also Kv1.3 inhibitors that are in development for atopic dermatitis (eczema) and eye diseases respectively. Atopic Dermatitis is a chronic inflammatory autoimmune disease, which results in itching, scratching, redness, scaling, insomnia and loss of skin surface. Uveitis and autoimmune dry eye syndrome are chronic life-long, inflammatory eye diseases, which can cause irreversible vision damage.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI's plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI's business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Dan Eramian, deramian@kpitherapeutics.com, 425-306-8716